Does curcumin delay time to prostate cancer recurrence in men on IADT?

The results of a small, randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients already treated on intermittent androgen deprivation therapy (IADT) have recently been published. … READ MORE …

IADT — pro and con; a follow-up

The other day we mentioned two articles in a recent issue of JAMA Oncology that dealt with the role of intermittent androgen deprivation therapy (IADT) in the management of progressive prostate cancer today. We have now had the good fortune to be able to read both of the two articles in full, thanks to a kind correspondent. … READ MORE …

Starting the new year with two of the usual controversies

Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …

CADT and IADT in the management of progressive and advanced prostate cancer

The debate over the relative values of continuous (CADT) and intermittent (IADT) forms of androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer has now been ongoing for years. … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

New meta-analysis endorses IADT for good responders to initial CADT

A new meta-analysis of data from nine large clinical trials suggests that, “There is fair evidence to recommend use of [intermittent] instead of [continuous androgen deprivation] for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation.” … READ MORE …

IADT: the still unanswered questions and choices that must be made

About 18 months ago, at the 2011 Genitourinary Cancer symposium in Orlando, Florida, Klotz et al. presented data from a large trial of intermittent (IADT) versus continuous androgen deprivation therapy (CADT) in the management of men with progressive prostate cancer after prior treatment with first- or second-line radiation therapy. We reported their data at the time. … READ MORE …